They recommend identification of prescribing barriers for high-intensity statin therapy and incorporation of these barriers into decision pathways and/or provider education. The researchers concluded that results of the current study demonstrate that prescribers do not appear to be following the package insert dosing recommendations for rosuvastatin, based on the fact that the severity of a patient’s CKD does not affect the prescribing pattern of high-intensity statin therapy. The researchers found that in 67.6% (25 of 37) of the patients, rosuvastatin was not renally adjusted in an appropriate manner ( P =.0240). No statistically significant differences were observed between the groups with respect to the proportion of high-intensity statins that were prescribed. Further, a lower percentage of White individuals was reported in the group with an eGFR <30 mL/min/1.73 m 2. Patients with eGFR <30 mL/min/1.73 m 2 were found to have a higher mean systolic blood pressure and were more likely to have diabetes or heart failure compared with those with eGFR ≥30 to 59 mL/min/1.73 m 2. Secondary study outcomes included the proportion of patients on a US Food and Drug Administration–approved renal dose adjustment of rosuvastatin, the mean difference in low-density lipoprotein cholesterol levels between the 2 groups, and differences in prescribing patterns of low-intensity to moderate-intensity statins between the 2 groups. The primary study outcome was the proportion of patients with ASCVD who were prescribed high-intensity statin therapy with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m 2 compared with those with an eGFR ≥30 to 59 mL/min/1.73 m 2. The study assessed electronic health records of patients between 18 and 89 years of age who received treatment within the University of Colorado Health System from January 1, 2020, through September 30, 2021.
0 kommentar(er)
